False negatives force Trinity Biotech syphilis test recall:
This article was originally published in Clinica
Executive Summary
Trinity Biotech, based in Bray, Ireland, has recalled certain lots of its CAPTIA Syphilis G Elisa test kit. The test, which is used to detect syphilis in the blood and to screen blood and/or plasma donors, has been recalled due to the risk of providing false negatives. Shifts in the performance of lots K00841, K00842, K00838, K00839, which were sold in the US in May 2002, can result in low positive readings equivalent to negatives, says the FDA's Center for Devices and Radiological Health.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.